High-dose imatinib improves cytogenetic and molecular remissions in patients with pretreated Philadelphia-positive, BCR-ABL-positive chronic phase cronich myeloid leukemia: first result from the randomized CELSG phrase III CML 11 "ISTAHIT"study

Petzer, A., Goranov, S. High-dose imatinib improves cytogenetic and molecular remissions in patients with pretreated Philadelphia-positive, BCR-ABL-positive chronic phase cronich myeloid leukemia: first result from the randomized CELSG phrase III CML 11 "ISTAHIT"study. Pavia: 2010 908-913,.

Petzer, A., Goranov, S. High-dose imatinib improves cytogenetic and molecular remissions in patients with pretreated Philadelphia-positive, BCR-ABL-positive chronic phase cronich myeloid leukemia: first result from the randomized CELSG phrase III CML 11 "ISTAHIT"study. Pavia: 2010 908-913,.

Petzer, A., Goranov, S. (2010) High-dose imatinib improves cytogenetic and molecular remissions in patients with pretreated Philadelphia-positive, BCR-ABL-positive chronic phase cronich myeloid leukemia: first result from the randomized CELSG phrase III CML 11 "ISTAHIT"study, Pavia: 908-913,.

Petzer, A., & Goranov, S. (2010). High-dose imatinib improves cytogenetic and molecular remissions in patients with pretreated Philadelphia-positive, BCR-ABL-positive chronic phase cronich myeloid leukemia: first result from the randomized CELSG phrase III CML 11 "ISTAHIT"study. Pavia: 908-913.